

Financial Tear Sheet

Corporate Profile

MyoKardia is a clinical stage biopharmaceutical company pioneering a precision medicine approach to discover, develop and commercialize targeted therapies for the treatment of serious and neglected rare cardiovascular diseases. MyoKardia's initial focus is on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. MyoKardia has used its precision medicine platform to generate a pipeline of therapeutic programs for the chronic treatment of the two most prevalent forms of heritable cardiomyopathy —hypertrophic cardiomyopathy, or HCM, and dilated cardiomyopathy, or DCM.

Stock Information

MYOK (Common Stock)

Exchange NASDAQ GS (US Dollar)

Price \$13.90


Change (%) • 0.45 (3.35%)

Volume 166,470 **52 Week Low** \$10.55

Market Cap \$423,081,774

Rolling EPS -0.63 PE Ratio 0

Shares Outstanding31,455,894 Data as of 07/20/17 4:00 p.m. ET



Recent Press Releases

05/09/17

MyoKardia Reports First Quarter 2017 Financial Results and Operational Progress

05/02/17

MyoKardia to Announce First Quarter 2017 Financial Results and Host Conference Call on Tuesday, May 9, 2017

Upcoming Events

There are currently no events scheduled.

SEC Filings

<< First | Previous | Next | Last >>

Filing Date	Form	Description	Filing Group	Downloads			
07/10/17	S-3	Simplified registration form	Registration Statements		*	围	
06/19/17	8-K	Report of unscheduled material events or corporate event	Current Reports	©		围	
06/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5			B	
06/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5			B	
06/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5			B	
06/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5			B	
06/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5			B	

06/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5	©		
06/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5	©	×	
06/16/17	4	Statement of changes in beneficial ownership of securities	3,4,5	©		

<< First | Previous | Next | Last >>

Corporate Governance

Tassos Gianakakos Chief Executive Officer

Jonathan Fox, M.D., Ph.D.Chief Medical Officer

Jake Bauer Vice President, Business Development and Business Operations

Ingrid Boyes Senior Vice President, Human Resources

Steven Chan Vice President, Corporate Controller

Joseph Lambing, Ph.D. Senior Vice President, Nonclinical and Pharmaceutical Development

Robert McDowell Senior Vice President of Drug Discovery

Iris Roth, Ph.D. Vice President, Program Team Leader